Comparative Effect of Zoledronate at 6 Versus 18 Months Following Denosumab Discontinuation

A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass Gains

(2020) Judith Everts‐Graber et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial

(2020) Anne Sophie Sølling et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Delayed Denosumab Injections and Fracture Risk

(2020) Kristine E. Ensrud et al.   ANNALS OF INTERNAL MEDICINE

Delayed Denosumab Injections and Fracture Risk Among Patients With Osteoporosis

(2020) Houchen Lyu et al.   ANNALS OF INTERNAL MEDICINE

The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis

(2020) Polyzois Makras et al.   BONE

Stopping Denosumab

(2019) Olivier Lamy et al.   Current Osteoporosis Reports

Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2‐year Clinical Trial

(2019) Athanasios D. Anastasilakis et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment

(2017) Athanasios D Anastasilakis et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension

(2017) Steven R Cummings et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases

(2017) Athanasios D Anastasilakis et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Observations following discontinuation of long-term denosumab therapy

(2017) M. R. McClung et al.   OSTEOPOROSIS INTERNATIONAL

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension

(2017) Henry G Bone et al.   Lancet Diabetes & Endocrinology